Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 255-280-9 | CAS number: 41253-21-8
Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- other information
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 978
- Report date:
- 1978
Materials and methods
- Objective of study:
- distribution
- excretion
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 417 (Toxicokinetics)
- Deviations:
- not specified
- GLP compliance:
- no
- Remarks:
- Study pre-dates GLP
Test material
- Reference substance name:
- 1,2,4-triazole
- EC Number:
- 206-022-9
- EC Name:
- 1,2,4-triazole
- Cas Number:
- 288-88-0
- Molecular formula:
- C2H3N3
- IUPAC Name:
- 1H-1,2,4-triazole
- Details on test material:
- - Name of test material (as cited in study report): 1,2,4-Triazol
- Locations of the label (if radiolabelling): 14C-labelled 1,2,4-Triazol
Constituent 1
- Radiolabelling:
- yes
- Remarks:
- 14C-labelled 1,2,4-Triazol
Test animals
- Species:
- rat
- Strain:
- not specified
- Sex:
- male
Administration / exposure
- Route of administration:
- other: Oral, intravenous, and intraduodenal
- Vehicle:
- not specified
Doses / concentrations
- Remarks:
- Doses / Concentrations:
0.1-100 mg/kg (intravenous); 1 mg/kg (oral); 1 mg/kg (intraduodenal)
- Details on study design:
- The study has been performed with 14C-labeled 1,2,4-triazol applied to the male rat. Application routes were intraveneous (0.1-100 mg/kg), oral (1 mg/kg) and intraduodenal (1 mg/kg).
Results and discussion
Toxicokinetic / pharmacokinetic studies
- Details on distribution in tissues:
- The applied radioactivity was evenly distributed by the circulation to all tissues. All tissue concentrations were similar and did not indicate any tissue preference. This pattern was stable and did not change until complete excretion. Full body autoradiography showed transient enhanced concentrations in the eye.
- Details on excretion:
- The analysis showed a nearly complete renal elimination of radioactivity in the rat. About 3-4% of the applied dose was excreted with the feces. The renal elimination occurred fast, the plasma half-life was about 12 hours and was independent of the dose applied. Experiments with animals surgically treated with a bile duct-duodenal fistula (cholangiostomy) showed that 15-20% of the applied dose was subjected to enterohepatic circulation.
Applicant's summary and conclusion
- Conclusions:
- Interpretation of results (migrated information): no bioaccumulation potential based on study results
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
